Clinical Trial Detail

NCT ID NCT02729896
Title A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab

Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq

Age Groups: adult senior

No variant requirements are available.